Anti-Fibrinolytic Drugs - Qatar

Qatar

The Anti-Fibrinolytic Drugs market in Qatar is projected to reach a revenue of US$7.24m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 5.18%, resulting in a market volume of US$9.32m by 2029.
In global comparison, United States will generate the highest revenue, with US$9,858.00m in 2024.
Qatar is witnessing a growing demand for anti-fibrinolytic drugs due to an increasing prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Qatar has been showing positive growth in recent years.

Customer preferences: Qatar has a high prevalence of cardiovascular diseases, which has led to an increase in demand for anti-fibrinolytic drugs. The elderly population in the country has also been a significant customer group for these drugs.

Trends in the market: The market for anti-fibrinolytic drugs in Qatar has been growing due to the increasing prevalence of cardiovascular diseases. The growth rate has been steady, and the market is expected to grow further in the coming years. The market is dominated by a few key players, with limited competition.

Local special circumstances: Qatar has a high prevalence of cardiovascular diseases due to a sedentary lifestyle, unhealthy diet, and a high prevalence of risk factors such as hypertension and diabetes. The country has been investing in improving its healthcare infrastructure, which has led to an increase in demand for anti-fibrinolytic drugs.

Underlying macroeconomic factors: Qatar has a high GDP per capita, which has led to an increase in healthcare spending. The country has been investing in improving its healthcare infrastructure, which has led to an increase in demand for anti-fibrinolytic drugs. The government has also been providing subsidies for healthcare, which has made healthcare more accessible to the general population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.